294 related articles for article (PubMed ID: 29541073)
21. Tumor Necrosis Factor α and Regulatory T Cells in Oncoimmunology.
Salomon BL; Leclerc M; Tosello J; Ronin E; Piaggio E; Cohen JL
Front Immunol; 2018; 9():444. PubMed ID: 29593717
[TBL] [Abstract][Full Text] [Related]
22. TNFR2 signaling modulates immunity after allogeneic hematopoietic cell transplantation.
Mancusi A; Alvarez M; Piccinelli S; Velardi A; Pierini A
Cytokine Growth Factor Rev; 2019 Jun; 47():54-61. PubMed ID: 31122819
[TBL] [Abstract][Full Text] [Related]
23. Reduction of Foxp3+ T cell subsets involved in incidence of chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.
Hu Y; Cui Q; Ye Y; Luo Y; Tan Y; Shi J; Huang H
Hematol Oncol; 2017 Mar; 35(1):118-124. PubMed ID: 26439896
[TBL] [Abstract][Full Text] [Related]
24. Granzyme A Is Required for Regulatory T-Cell Mediated Prevention of Gastrointestinal Graft-versus-Host Disease.
Velaga S; Ukena SN; Dringenberg U; Alter C; Pardo J; Kershaw O; Franzke A
PLoS One; 2015; 10(4):e0124927. PubMed ID: 25928296
[TBL] [Abstract][Full Text] [Related]
25. Third-party regulatory T cells prevent murine acute graft-versus-host disease.
Lim JY; Im KI; Song Y; Kim N; Nam YS; Jeon YW; Cho SG
Korean J Intern Med; 2018 Sep; 33(5):980-989. PubMed ID: 29050459
[TBL] [Abstract][Full Text] [Related]
26. TGF-β-Induced CD8
Zhong H; Liu Y; Xu Z; Liang P; Yang H; Zhang X; Zhao J; Chen J; Fu S; Tang Y; Lv J; Wang J; Olsen N; Xu A; Zheng SG
Front Immunol; 2018; 9():35. PubMed ID: 29441062
[TBL] [Abstract][Full Text] [Related]
27. The promise of CD4
Copsel S; Wolf D; Komanduri KV; Levy RB
Haematologica; 2019 Jul; 104(7):1309-1321. PubMed ID: 31221786
[TBL] [Abstract][Full Text] [Related]
28. Regulatory T Cell Therapy of Graft-versus-Host Disease: Advances and Challenges.
Hefazi M; Bolivar-Wagers S; Blazar BR
Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34575843
[TBL] [Abstract][Full Text] [Related]
29. Combination cell therapy using mesenchymal stem cells and regulatory T-cells provides a synergistic immunomodulatory effect associated with reciprocal regulation of TH1/TH2 and th17/treg cells in a murine acute graft-versus-host disease model.
Lim JY; Park MJ; Im KI; Kim N; Jeon EJ; Kim EJ; Cho ML; Cho SG
Cell Transplant; 2014 Apr; 23(6):703-14. PubMed ID: 23452894
[TBL] [Abstract][Full Text] [Related]
30. Induced regulatory T cells promote tolerance when stabilized by rapamycin and IL-2 in vivo.
Zhang P; Tey SK; Koyama M; Kuns RD; Olver SD; Lineburg KE; Lor M; Teal BE; Raffelt NC; Raju J; Leveque L; Markey KA; Varelias A; Clouston AD; Lane SW; MacDonald KP; Hill GR
J Immunol; 2013 Nov; 191(10):5291-303. PubMed ID: 24123683
[TBL] [Abstract][Full Text] [Related]
31. Role of Regulatory T Cells in Tumor-Bearing Mice Treated with Allo-Hematopoietic Stem Cell Transplantation Plus Thymus Transplantation.
Hosaka N
J Immunol Res; 2018; 2018():7271097. PubMed ID: 30057919
[TBL] [Abstract][Full Text] [Related]
32. Generation of allo-antigen-specific induced Treg stabilized by vitamin C treatment and its application for prevention of acute graft versus host disease model.
Kasahara H; Kondo T; Nakatsukasa H; Chikuma S; Ito M; Ando M; Kurebayashi Y; Sekiya T; Yamada T; Okamoto S; Yoshimura A
Int Immunol; 2017 Dec; 29(10):457-469. PubMed ID: 29126272
[TBL] [Abstract][Full Text] [Related]
33. Role of CD4+CD25+highFoxp3+CD62L+ regulatory T cells and invariant NKT cells in human allogeneic hematopoietic stem cell transplantation.
Vela-Ojeda J; Montiel-Cervantes L; Granados-Lara P; Reyes-Maldonado E; García-Latorre E; Garcia-Chavez J; Majluf-Cruz A; Mayani H; Borbolla-Escoboza JR; Esparza MG
Stem Cells Dev; 2010 Mar; 19(3):333-40. PubMed ID: 19919293
[TBL] [Abstract][Full Text] [Related]
34. Regulatory T cell immunotherapy for transplantation tolerance: step into clinic.
Jiang S; Tsang J; Tam P
Int Immunopharmacol; 2010 Dec; 10(12):1486-90. PubMed ID: 20736096
[TBL] [Abstract][Full Text] [Related]
35. Host Foxp3+CD4+ Regulatory T Cells Act as a Negative Regulator of Dendritic Cells in the Peritransplantation Period.
Inoue T; Ikegame K; Kaida K; Okada M; Yoshihara S; Tamaki H; Fujimori Y; Soma T; Ogawa H
J Immunol; 2016 Jan; 196(1):469-83. PubMed ID: 26621858
[TBL] [Abstract][Full Text] [Related]
36. Antigen-specific regulatory T cells--ex vivo expansion and therapeutic potential.
Masteller EL; Tang Q; Bluestone JA
Semin Immunol; 2006 Apr; 18(2):103-10. PubMed ID: 16458533
[TBL] [Abstract][Full Text] [Related]
37. IFN-γ production by allogeneic Foxp3+ regulatory T cells is essential for preventing experimental graft-versus-host disease.
Koenecke C; Lee CW; Thamm K; Föhse L; Schafferus M; Mittrücker HW; Floess S; Huehn J; Ganser A; Förster R; Prinz I
J Immunol; 2012 Sep; 189(6):2890-6. PubMed ID: 22869903
[TBL] [Abstract][Full Text] [Related]
38. Clinical application of expanded CD4+25+ cells.
June CH; Blazar BR
Semin Immunol; 2006 Apr; 18(2):78-88. PubMed ID: 16458015
[TBL] [Abstract][Full Text] [Related]
39. A subset of CD8+ T cells acquiring selective suppressive properties may play a role in GvHD management.
Avivi I; Stroopinsky D; Rowe JM; Katz T
Transpl Immunol; 2013 Jan; 28(1):57-61. PubMed ID: 23196257
[TBL] [Abstract][Full Text] [Related]
40. Advances in the treatment of graft-versus-host disease with immunomodulatory cells.
Yu Q; Wang H; Zhang L; Wei W
Int Immunopharmacol; 2021 Mar; 92():107349. PubMed ID: 33486323
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
